Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer a systematic review and meta-analysis

JAMA

Volumn 305, Issue 22, 2011, Pages 2335-2342

  Biagi, James J ^a   Raphael, Michael J ^b   Mackillop, William J ^a,b   Kong, Weidong ^b   King, Will D ^a   Booth, Christopher M ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW;

EID: 79958035214     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.749     Document Type: Review

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55 (2):74-108.
2. National Institutes of Health. Adjuvant Therapy for Patients With Colon and Rectum Cancer: NIH Consensus Statement. Vol 8. Bethesda, MD: National Institutes of Health; 1990:1-25.
3. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-3419.
4. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004; 22(16):3395-3407.
5. Systemic treatment wait times. Cancer Care Ontario, Action Cancer Ontario. http://www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=8888. Accessed May 13, 2011.
6. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008;87(1):3-16.
7. Greenland S.Meta analysis. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia, PA: Lippincott-Raven; 1998:643-673.
8. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992; 135(11):1301-1309.
9. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
10. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-463.
11. Duval S, Tweedie RA. Nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95(449): 89-98.
12. Ahmed S, Ahmad I, Zhu T, et al. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum. 2010; 53(10):1432-1438.
13. Bayraktar UD, Chen E, Bayraktar S, et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? [published online December 17, 2010]. Cancer. doi:10.1002/cncr.25720.
14. Biagi JJ, Barnes C, O'Callaghan CJ. Time to adjuvant chemotherapy in colorectal cancer [abstract]. Presented at: 2007 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 21, 2007; Orlando, FL.
15. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005;16(4):549-557.
16. Cheung WY, Neville BA, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and their impact on outcomes for stage II and III rectal cancer. Dis Colon Rectum. 2009;52(6):1054-1063.
17. Czaykowski P, Gill S, Kennecke H, Turner D, Gordon V. Adjuvant chemotherapy (AC) for stage 3 colon cancer: does timing matter? [abstract]. Presented at: 2007 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 21, 2007; Orlando, FL.
18. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107(11):2581-2588.
19. Lima IS, Yasui Y, Scarfe A, Winget M. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada [published online February 11, 2011]. Cancer. doi:10.1002/cncr.25954.
20. Wadd N, Borowski D, Bharathan B, Kelly S, Bradburn D, Wilson R. Timing of adjuvant chemotherapy in Dukes' stage C colorectal cancer: does a delayed start of treatment affect outcome? [abstract]. Ann Oncol. 2008;19(suppl 6):24.
21. Zeig-Owens R, Gershman ST, Knowlton R, Jacobson JS. Survival and time interval from surgery to start of chemotherapy among colon cancer patients. J Registry Manag. 2009;36(2):30-41.
22. McCulloch P, Choy A. Effect of menstrual phase on surgical treatment of breast cancer. Lancet. 1994; 344(8919):402-403.
23. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79(2):185-188. (Pubitemid 24324908)
24. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82(1):4-6.
25. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39(10):3861-3865. (Pubitemid 10242198)
26. Ono I, Gunji H, Suda K, Iwatsuki K, Kaneko F. Evaluation of cytokines in donor site wound fluids. Scand J Plast Reconstr Surg Hand Surg. 1994;28 (4):269-273.
27. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery. 1987; 102(1):71-78. (Pubitemid 17102951)
28. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63(11-12):1727-1733. (Pubitemid 10138923)
29. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104(24):10158- 10163. (Pubitemid 47175279)
30. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445(7123):106-110. (Pubitemid 46067310)
31. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111- 115. (Pubitemid 46067311)
32. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
33. Mackillop WJ. Killing time: the consequences of delays in radiotherapy. Radiother Oncol. 2007; 84(1):1-4. (Pubitemid 47030687)
34. Adjuvant! Online: Decision making tools for health care professionals. http://www.adjuvantonline.com. Accessed October 8, 2010.
35. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350 (23):2343-2351.
36. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-2204. (Pubitemid 46954643)
37. Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? a meta-analysis. Eur J Cancer. 2010;46(6): 1049-1055.
38. Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol. 2008;19 (2):400-402.
39. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ; Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370(9604):2020-2029.
40. André T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25(24):3732-3738. (Pubitemid 47372615)
41. Taal BG, Van Tinteren H, Zoetmulder FA; NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 2001;85(10):1437-1443. (Pubitemid 34001570)
42. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-249.
43. Lacy AM, García-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359(9325):2224- 2229. (Pubitemid 34717975)
44. Ng CS, Whelan RL, Lacy AM, Yim AP. Is minimal access surgery for cancer associated with immunologic benefits? World J Surg. 2005;29(8):975-981.
45. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V; Evidence-Based Medicine Working Group. Users' guides to the medical literature: IV, how to use an article about harm. JAMA. 1994;271(20):1615-1619.